第三剂 BNT162b2 mRNA 疫苗的有效性。
Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine.
机构信息
Division of Data and Digital Health, Maccabi HealthCare Services, Tel Aviv-Jaffa, Israel.
出版信息
J Infect Dis. 2022 Jan 5;225(1):30-33. doi: 10.1093/infdis/jiab556.
Abstract
A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of nearly 1 million members receiving 2 doses of BNT162b2 in January-February 2021, infection rates (based on polymerase chain reaction results) were compared between those who received a third dose with those who did not during August-October 2021 (maximum, 70 days). Crude VE was 92.9% (95% confidence interval [CI], 92.6%-93.2%) and adjusted VE was 89.1% (95% CI, 87.5%-90.5%). We conclude that the third dose provides added protection against SARS-CoV-2 infection for those vaccinated 6 months ago.
摘要
一项在以色列大型健康维护组织中进行的回顾性队列研究旨在确定第三剂 BNT162b2 疫苗对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的疫苗有效性（VE）。在 2021 年 1 月至 2 月期间，近 100 万名接受了 2 剂 BNT162b2 接种的成员中，在 2021 年 8 月至 10 月期间（最长 70 天），比较了接受第三剂疫苗接种者和未接受第三剂疫苗接种者的感染率（基于聚合酶链反应结果）。未经调整的 VE 为 92.9%（95%置信区间[CI]，92.6%-93.2%），调整后的 VE 为 89.1%（95% CI，87.5%-90.5%）。我们的结论是，对于 6 个月前接种疫苗的人来说，第三剂疫苗提供了针对 SARS-CoV-2 感染的额外保护。
相似文献
1
Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine.第三剂 BNT162b2 mRNA 疫苗的有效性。
J Infect Dis. 2022 Jan 5;225(1):30-33. doi: 10.1093/infdis/jiab556.
2
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.辉瑞-生物科技 BNT162b2 mRNA 疫苗预防非免疫功能低下 5-17 岁儿童和青少年与 COVID-19 相关的急诊和紧急护理就诊及住院的有效性 - VISION 网络，10 个州，2021 年 4 月-2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Mar 4;71(9):352-358. doi: 10.15585/mmwr.mm7109e3.
3
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.2 剂 BNT162b2（辉瑞-生物科技）mRNA 疫苗预防 5-11 岁儿童和 12-15 岁青少年感染 SARS-CoV-2 的效果 - PROTECT 队列，2021 年 7 月至 2022 年 2 月。
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):422-428. doi: 10.15585/mmwr.mm7111e1.
4
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.以色列卫生保健工作者中，第三剂 BNT162b2 疫苗接种与 SARS-CoV-2 感染发生率的关联。
JAMA. 2022 Jan 25;327(4):341-349. doi: 10.1001/jama.2021.23641.
5
Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021.辉瑞-生物科技和莫德纳疫苗第三剂在预防免疫功能正常和免疫功能低下成年人 COVID-19 住院方面的有效性-美国，2021 年 8 月至 12 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):118-124. doi: 10.15585/mmwr.mm7104a2.
6
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine.接种 3 剂与 2 剂 BNT162b2 mRNA 疫苗后 SARS-CoV-2 检测呈阳性的几率。
JAMA Intern Med. 2022 Feb 1;182(2):179-184. doi: 10.1001/jamainternmed.2021.7382.
7
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间，mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
8
Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).六家以色列医院（CoVEHPI）医护人员中 BNT162b2 新冠疫苗预防 SARS-CoV-2 感染的早期效果。
Vaccine. 2022 Jan 24;40(3):512-520. doi: 10.1016/j.vaccine.2021.11.092. Epub 2021 Dec 10.
9
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
10
Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.高风险人群中 3 剂与 2 剂严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）mRNA 疫苗的疫苗有效性。
Clin Infect Dis. 2022 Aug 24;75(1):e579-e584. doi: 10.1093/cid/ciac178.
引用本文的文献
1
Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.异源和同源 COVID-19 加强疫苗接种的抗体反应比较：一项观察性研究。
Front Immunol. 2024 Nov 13;15:1448408. doi: 10.3389/fimmu.2024.1448408. eCollection 2024.
2
Advancements in the Development of Anti-SARS-CoV-2 Therapeutics.抗 SARS-CoV-2 治疗药物的研发进展。
Int J Mol Sci. 2024 Oct 9;25(19):10820. doi: 10.3390/ijms251910820.
3
Time-course analysis of antibody and cytokine response after the third SARS-CoV-2 vaccine dose.第三次接种新型冠状病毒2疫苗后抗体和细胞因子反应的时间进程分析。
Vaccine X. 2024 Sep 24;20:100565. doi: 10.1016/j.jvacx.2024.100565. eCollection 2024 Oct.
4
Comparison of long-term anti-RBD SARS-CoV-2 antibody response following different vaccination schemes in Tunisia.突尼斯不同疫苗接种方案后长期抗 RBD SARS-CoV-2 抗体应答的比较。
Tunis Med. 2024 Aug 5;102(8):457-464. doi: 10.62438/tunismed.v102i8.4944.
5
Anti-SARS-CoV-2 Antibodies Level and COVID-19 Vaccine Boosters among Healthcare Workers with the Highest SARS-CoV-2 Infection Risk-Follow Up Study.SARS-CoV-2感染风险最高的医护人员中抗SARS-CoV-2抗体水平与COVID-19疫苗加强针——随访研究
Vaccines (Basel). 2024 Apr 29;12(5):475. doi: 10.3390/vaccines12050475.
6
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.血液系统恶性肿瘤患者和老年人群对三剂抗 SARS-CoV-2 BNT162b2 疫苗的体液和细胞反应动力学。
Front Immunol. 2024 Jan 26;14:1221587. doi: 10.3389/fimmu.2023.1221587. eCollection 2023.
7
Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence.针对新型病原体的疫苗接种：对 COVID-19 疫苗有效性证据的批判性综述
Microorganisms. 2023 Dec 31;12(1):89. doi: 10.3390/microorganisms12010089.
8
Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study.设计和分析 COVID-19 加强针有效性的观察性研究中的异质性：综述和案例研究。
Sci Adv. 2023 Dec 22;9(51):eadj3747. doi: 10.1126/sciadv.adj3747. Epub 2023 Dec 20.
9
Immunogenicity of ChAdOx1 (Covishield) Booster Dose in Healthcare Providers: A Pre-Post Study.医疗保健人员中ChAdOx1（Covishield）加强剂量的免疫原性：一项前后对照研究。
Cureus. 2023 Oct 2;15(10):e46370. doi: 10.7759/cureus.46370. eCollection 2023 Oct.
10
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states.加强型 mRNA 疫苗接种和 SARS-CoV-2 奥密克戎感染对免疫功能低下状态下 T 细胞免疫的叠加效应。
Sci Transl Med. 2023 Jul 12;15(704):eadg9452. doi: 10.1126/scitranslmed.adg9452.
本文引用的文献
1
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.辉瑞-BioNTech 信使核糖核酸 COVID-19 疫苗在美国大型综合卫生系统中的 6 个月有效性：一项回顾性队列研究。
Lancet. 2021 Oct 16;398(10309):1407-1416. doi: 10.1016/S0140-6736(21)02183-8. Epub 2021 Oct 4.
2
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.辉瑞-BioNTech 疫苗加强针在以色列预防新冠病毒。
N Engl J Med. 2021 Oct 7;385(15):1393-1400. doi: 10.1056/NEJMoa2114255. Epub 2021 Sep 15.
3
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.以色列全国疫苗接种运动后，mRNA BNT162b2疫苗对SARS-CoV-2感染及COVID-19病例、住院和死亡的影响与效果：一项利用国家监测数据的观察性研究
Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5.
4
COVID-19 vaccine impact in Israel and a way out of the pandemic.新冠疫苗在以色列的影响以及走出疫情大流行的途径。
Lancet. 2021 May 15;397(10287):1783-1785. doi: 10.1016/S0140-6736(21)01018-7. Epub 2021 May 5.
5
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
6
Covid-19: FDA panel votes to approve Pfizer BioNTech vaccine.新冠疫情：美国食品药品监督管理局专家小组投票批准辉瑞生物科技公司的疫苗。
BMJ. 2020 Dec 11;371:m4799. doi: 10.1136/bmj.m4799.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
Zotero 插件